Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

Big names for Wellington Water board
Finance

Big names for Wellington Water board

Credit rating agency warns that water reforms are no council debt panacea.

Pattrick Smellie 31 Oct 2025
RBNZ cuts number of jobs by 20%
Finance

RBNZ cuts number of jobs by 20%

The Reserve Bank claims $11m of cost savings via Project Denby’s 20% job cuts.

Staff reporters 29 Oct 2025
Kiwibank wary of capital-review barrier to growth
Finance

Kiwibank wary of capital-review barrier to growth

Kiwibank raises issues of competitive advantage.

Andy Macdonald 24 Oct 2025